-
Cancer Drugs Fund poor value for money, study finds
pharmatimes
May 02, 2017
England’s Cancer Drugs Fund is poor value for money and may be exposing patients to unnecessary harm, concludes ...
-
England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'
worldpharmanews
May 02, 2017
Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily from toxic side effects of the dru
-
Studying unstable chromosomes can help predict cancer relapse, says Cancer Research UK
pharmaceutical-technology
April 28, 2017
Cancer Research UK-funded TRACERx lung cancer study has claimed that unstable chromosomes within lung tumours ...
-
Blood test able to detect cancer a year in advance
pharmafile
April 28, 2017
A team at the Francis Crick Institute, based in London, has discovered a new way of analysing blood in patients...
-
Money Pressures Mount When a Spouse Gets Cancer
drugs.com
April 28, 2017
Family income can take a big hit when a wife or husband cares for a spouse with cancer, researchers report.
-
UK NCRI introduces five-year strategy to advance cancer research
pharmaceutical-technology
April 27, 2017
UK NCRI introduces five-year strategy to advance cancer research - Pharmaceutical Technology
-
FDA condemns 14 companies selling fraudulent cancer 'cures' online
pharmafile
April 27, 2017
The FDA has struck out against a wave of companies offering cancer treatments online which fraudulently...
-
One third of cancer cases in England diagnosed as emergency
pharmatimes
April 26, 2017
More than one third (34 percent) of patients with cancer diagnosed as an emergency in England had not visited their GP beforehand...
-
Oxford Cancer Biomarkers licenses rights to China for three colorectal cancer tests
biospectrumasia
April 25, 2017
Oxford Cancer Biomarkers (OCB) said it will expand the use of three of its in vitro diagnostic tests for colorectal cancer into China through a partnership with MBM.
-
England “really is not a good place” to get cancer, BMS UK General Manager says
pharmafile
April 25, 2017
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in